Patients taking GLP-1 weight-loss medicines such as Wegovy and Mounjaro may be eating too little of several key nutrients because their suppressed appetite quietly shrinks their diets, a small English study published on Monday in BMJ Nutrition Prevention & Health finds — and most had no idea.
The study comes from researchers at the University of Oxford, the NNEdPro Global Institute for Food, Nutrition and Health, and Ulster University. It matters because obesity and type 2 diabetes care is now built around these injectable drugs, yet — as the researchers themselves note — “no drug-specific nutritional monitoring framework exists.”
The team asked 14 patients, ten privately prescribed and four on the NHS, at a single English general practice to record their diets over two days using the validated myfood24 diary. Doctors or dietitians assessing patients for nutrient shortfalls typically rely on diet recall of exactly this kind — but no routine system prompts it once treatment starts.
The average daily energy intake was 1,231 kilocalories, or 58.5% of sex-specific estimated requirements — well under what the body needs to sustain weight, muscle and micronutrient reserves. Three people ate fewer than 800 kcal a day.
Appetite suppression cuts food intake
- Appetite suppression works calorie-wise but also cuts the total food you eat — including the vitamins, minerals, and fiber inside it.
- Two participants only discovered how little they were eating when they filled in the diary — researchers say routine monitoring would be needed to catch this.
- Protein held up; fiber, vitamin D, iron, potassium and magnesium often did not.
Which nutrients fell short, and by how much
Each participant’s intake was compared with official UK reference nutrient intake (RNI) values — the government’s estimates of how much of each nutrient most people need. A shortfall was deemed clinically relevant when intake fell below two-thirds of the RNI.
Of 28 nutrients assessed, average intakes were below that threshold in ten people. More than three-quarters of the group fell short on both fiber and vitamin D; half fell short on iron. Fruit and vegetable intake was below the recommended 400 grams in all 14 participants.
Protein was the exception, averaging 153% of the RNI, with only one participant below target. Ultra-processed foods, used as a proxy for poor diet quality, supplied 33% of energy on average — though one participant drew 84% of their calories from UPFs.
| Measure | Finding | Source detail |
|---|---|---|
| Daily energy intake | 1,231 kcal (58.5% of requirements) | Three people below 800 kcal/day |
| Protein | 153% of RNI on average | Only one participant short |
| Fruit and vegetables | All 14 below 400 g/day | UK “5-a-day” level |
The care gap around the prescription
Participants consistently linked their reduced intake to appetite suppression. Many described no structured follow-up to track progress or raise concerns. Inadequate medication reviews left side effects such as dizziness and low blood pressure unmanaged, with some patients adjusting their own schedules or turning to online peer groups.
“This highlighted a broader gap in professional oversight and safe integration of weight-reduction treatments with existing medications,” the researchers note.
The drugs also carried smaller, unexpected changes. Participants reported reduced alcohol intake, less pleasure from food, avoidance of social eating due to nausea or diarrhea, and anxiety about regaining weight or affording treatment long term. Many also described reduced “food noise” — the constant, intrusive thoughts about eating — as a benefit they did not want to lose.
“Current U.K. dietary advice is based on the Eatwell Guide, a weight-neutral guide not designed for people with malnutrition in obesity or those on incretin-based therapies,” the researchers highlight. Incretin-based therapies is the umbrella term for GLP-1 and dual GIP/GLP-1 receptor agonists — the drug classes behind Wegovy and Mounjaro.
Privately prescribed patients dominated this cohort, and the researchers point out that “nutritional safety netting may be particularly sparse outside NHS pathways.”
How much weight the findings can carry
These are early, exploratory figures, and the limits matter as much as the numbers. This is an observational study — one that watches what happens rather than assigning treatments — so no conclusions about cause and effect can be drawn. The sample is tiny and came from one general practice in a relatively affluent English area, so the pattern may not hold elsewhere.
Still, the numbers give a concrete benchmark for what needs watching: two participants were “shocked” by how little they were eating once they saw their own diaries — something that, the researchers suggest, would go unnoticed without any form of monitoring.
“This exploratory service evaluation suggests that some patients prescribed [appetite suppressant] therapies may consume very-low-energy diets and fall short of key micronutrient targets despite adequate protein intake,” the team concludes.
What the findings change
The funding for this research was not disclosed in the available source material. The full academic article, Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists, names Dhanush Ammineni, Milou Ottolini, Sumantra Ray and colleagues across its five authors.
References
- Ammineni, D., Ottolini, M., Ray, S. et al., Uncovering nutritional deficiencies and the adequacy of wrap-around care for patients on GLP-1 and dual GIP/GLP-1 receptor agonists, BMJ Nutrition Prevention & Health (2026). DOI: 10.1136/bmjnph-2026-001622 — https://doi.org/10.1136/bmjnph-2026-001622
- Medical Xpress, GLP-1 weight-loss drugs linked to inadequate intake of key nutrients in some people (2026).
Consult a qualified healthcare professional before making changes to prescription medication or diet.